Pacira Biosciences Inc PCRX:NASDAQ

Last Price$45.87Cboe Previous Close - Real-Time Last Sale as of 3:59PM ET 12/06/19
Cboe Real-Time Quotes
Today's Change0(0.00%)
Bid (Size)$42.47 (100)
Ask (Size)$47.94 (100)
Day Low / HighN/A - N/A
Volume306.5 K

View Pharmaceuticals: Other IndustryPeer Comparison as of 12/06/2019


Pacira Biosciences Inc ( NASDAQ )

Price: $45.87
Change: 0.00 (0.00%)
Volume: 306.5 K
3:59PM ET 12/06/2019

Prestige Consumer Healthcare Inc ( NYSE )

Price: $38.22
Change: 0.00 (0.00%)
Volume: 288.4 K
4:00PM ET 12/06/2019

Ironwood Pharmaceuticals Inc ( NASDAQ )

Price: $12.48
Change: +0.15 (1.22%)
Volume: 1.5 M
4:00PM ET 12/06/2019

Madrigal Pharmaceuticals Inc ( NASDAQ )

Price: $117.20
Change: +3.00 (2.63%)
Volume: 78.1 K
4:00PM ET 12/06/2019

Zogenix Inc ( NASDAQ )

Price: $46.86
Change: +1.28 (2.81%)
Volume: 505.6 K
4:00PM ET 12/06/2019

Read more news Recent News

Q4, 2019, 2020 Earnings Estimates for Pacira Biosciences Raised
3:06AM ET 11/09/2019 MT Newswires

Consensus estimates for Q4 ending December 31, 2019, and the full year forecasts for 2019 and 2020 for the years ending on December 31 for Pacira...

2019 Estimate for Pacira Biosciences Scaled Up but 2020 Earnings Number Scaled Down
2:56AM ET 11/08/2019 MT Newswires

The full year forecasted earnings estimates for 2019 and 2020 for Pacira Biosciences Inc (NASDAQ:PCRX, Recent Price: 42.62) have been changed. The...

Pacira BioSciences Q3 Non-GAAP EPS Beats, Revenue Just Short of Expectations
10:03AM ET 11/07/2019 MT Newswires

Pacira BioSciences (PCRX) on Thursday reported Q3 non-GAAP EPS of $0.48, compared with $0.31 a year earlier and the Capital IQ consensus forecast of $0.33....

Analyst Actions: BTIG Research Initiates Coverage on Pacira Pharmaceuticals With Buy Rating, $56 PT
9:33AM ET 11/06/2019 MT Newswires

Pacira Pharmaceuticals' (PCRX) average rating among analysts is a hold, with an average price target of $54. Price: 43.30, Change: +1.08, Percent Change:...

Company Profile

Business DescriptionPacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ. View company web site for more details
Address5 Sylvan Way
Parsippany, New Jersey 07054
Number of Employees518
Recent SEC Filing12/06/2019CT ORDER
Chairman, Chief Executive & Operating OfficerDavid M. Stack
PresidentMax Reinhardt
Chief Financial OfficerCharles A. Reinhart
Vice President-Research & DevelopmentVladimir Kharitonov

Company Highlights

Price Open$45.65
Previous Close$45.87
52 Week Range$34.64 - 49.50
Market Capitalization$1.9 B
Shares Outstanding41.7 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement02/27/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings1.1K
Earnings per Share$0.32
Beta vs. S&P 500N/A
Revenue$337.3 M
Net Profit Margin0.55%
Return on Equity0.65%

Analyst Ratings as of 11/04/2019

Consensus RecommendationConsensus Icon
Powered by Factset